• Shosaku Nomura, Kazuyoshi Ishii, Yuka Kamitsuji, Nobuhiko Uoshima, Emiko Ishikawa, Hitoshi Kitayama, and Kunio Hayashi.
• Division of Hematology at Kishiwada City Hospital, Kishiwada, Osaka, Japan. shosaku-n@mbp.ocn.ne.jp
• Clin. Appl. Thromb. Hemost. 2007 Apr 1; 13 (2): 206-12.

AbstractThis study measured and compared levels of some chemokines in patients with rituximab-treated non-Hodgkin lymphoma because they may participate in the mechanism of efficacy of rituximab in non-Hodgkin lymphoma patients. Monocytic chemotactant protein-1, RANTES (regulated on activation, normally T-cell expressed and secreted), eotaxin, interleukin-8, neutrophil-activating protein-78, stromal cell-derived factor-1, and growth-regulating oncogene-alpha in patients with rituximab-treated non-Hodgkin lymphoma were measured by enzyme-linked immunosorbent assay. Levels of RANTES were higher in non-Hodgkin lymphoma patients than in controls. Levels of monocytic chemotactant protein-1, RANTES, and neutrophil-activating protein-78 were significantly elevated before and after chemotherapy with rituximab treatment. However, the level of stromal cell-derived factor-1 did not exhibit a significant change. Before to after chemotherapy without rituximab treatment, all chemokine levels did not exhibit significant changes. These findings suggest that activated platelet-dependent chemokines such as RANTES and neutrophil-activating protein-78 may modulate the efficacy of rituximab in antibody-dependent cellular cytotoxity.

24 keywords...

hide…